{"product_id":"opko-business-model-canvas","title":"Opko Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpko Business Model Canvas: Quick, Actionable Insights for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Opko’s strategic playbook with our concise Business Model Canvas—discover how its value propositions, partnerships, and revenue streams interlock to drive growth and competitive advantage; perfect for investors, consultants, and founders seeking actionable, ready-to-use insights. Download the full Word \u0026amp; Excel canvas to analyze risks, benchmark strategies, and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer Global Commercialization Alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis alliance gives OPKO global reach for NGENLA, with Pfizer handling commercialization and OPKO receiving tiered royalties and milestone payments; Pfizer’s global sales network covered 125+ countries and drove NGENLA launches in the US and EU starting 2023. As of 2025 Pfizer’s commercialization scale helped NGENLA reach estimated annual sales of ~$220M, while OPKO’s royalty\/milestone receipts are projected at 15–25% of net sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVifor Fresenius Medical Care Renal Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Vifor Fresenius Medical Care Renal Pharma alliance commercializes Rayaldee outside the US, targeting ~40 million CKD patients globally; OPKO and Vifor\/Fresenius share development milestones and a tiered royalty where OPKO reports royalties of mid-teens to low-20s percent on net sales, supporting long-term revenue diversification and faster market access in specialist renal channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Systems and Sports Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Reference Laboratories holds contracts with major hospital systems and pro sports leagues, supplying diagnostic testing that contributed to Opko Health segment revenue of $172 million in 2024, securing steady volume and recurring billing. These preferred-provider relationships for complex diagnostics help protect market share in a US clinical lab market valued at about $120 billion in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOPKO partners with universities and research centers to advance its early-stage pipeline and diagnostics, accessing specialized talent and discovery platforms that supported 6 INDs and 12 biomarker validations from 2019–2024; this lowers R\u0026amp;D spend volatility by sharing costs and IP risks in preclinical and Phase 1 work.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: co-funded studies cut OPKO’s upstream spend by ~30% on projects tied to diagnostics, and university collaborations contributed to a 22% faster trial start-up in 2023 vs 2020.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to discovery tech and talent\u003c\/li\u003e\n\u003cli\u003eShared preclinical costs (~30% savings)\u003c\/li\u003e\n\u003cli\u003e6 INDs, 12 biomarkers (2019–2024)\u003c\/li\u003e\n\u003cli\u003e22% faster trial starts (2023 vs 2020)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors and Licensees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOPKO uses local distributors and licensees in Latin America and Europe to sell its pharma and device portfolio, leveraging partners' regulatory know-how and logistics to scale without big fixed costs; in 2024 international sales represented about 35% of OPKO's reported $1.05B revenue, helping preserve R\u0026amp;D spend (~$180M in 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of 2024 revenue from international markets\u003c\/li\u003e\n\u003cli\u003e$1.05B total 2024 revenue\u003c\/li\u003e\n\u003cli\u003e$180M R\u0026amp;D spend in 2024\u003c\/li\u003e\n\u003cli\u003eFaster market entry, lower capex, localized compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOPKO partnerships drive global sales, diagnostics scale \u0026amp; shared R\u0026amp;D—35% intl revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOPKO’s key partnerships (Pfizer, Vifor\/Fresenius, Bio-Reference, universities, local distributors) drive global commercialization, steady diagnostics volume, and shared R\u0026amp;D risk—supporting ~35% international revenue of $1.05B (2024), ~$220M NGENLA sales estimate (2025), $172M lab revenue (2024), and ~30% upstream cost savings from co-funded studies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eGlobal commercialization\u003c\/td\u003e\n\u003ctd\u003eNGENLA ~$220M (2025 est); royalties 15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVifor\/Fresenius\u003c\/td\u003e\n\u003ctd\u003eRayaldee ex‑US\u003c\/td\u003e\n\u003ctd\u003eTargets ~40M CKD patients; royalties mid‑teens–low‑20s%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio‑Reference\u003c\/td\u003e\n\u003ctd\u003eDiagnostics\/provider contracts\u003c\/td\u003e\n\u003ctd\u003e$172M lab revenue (2024); US lab market ~$120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\u003c\/td\u003e\n\u003ctd\u003eEarly R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6 INDs, 12 biomarkers (2019–24); ~30% cost savings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal distributors\u003c\/td\u003e\n\u003ctd\u003eIntl sales\/logistics\u003c\/td\u003e\n\u003ctd\u003e35% of $1.05B revenue (2024); R\u0026amp;D ~$180M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Opko that maps customer segments, channels, value propositions, key activities, resources, partners, cost structure and revenue streams, reflecting real-world operations and strategic plans for presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Opko’s business model with editable cells to quickly pinpoint revenue drivers, R\u0026amp;D priorities, and partnership dependencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOpko conducts discovery and clinical testing of novel biologics and small molecules for unmet needs, with R\u0026amp;D spend of $254 million in FY2024 driving programs in ophthalmology and endocrinology; its proprietary CTP (carboxy-terminal peptide) half-life extension platform underpins multiple candidates, extending protein half-life by 2–5x in preclinical studies, and successful trials are the main path to licensing deals and long-term value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Laboratory Diagnostic Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough Bio-Reference Laboratories, OPKO processes over 100 million tests annually (2024 report), from routine panels to advanced genomics, driving $805m lab services revenue in FY2024; this requires automated high-throughput labs, cold-chain logistics, and ~7,000+ medical technicians to sustain accuracy and turnaround that protect diagnostic margins and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko deploys a specialized internal sales force to market proprietary products like Rayaldee, with field teams directly engaging nephrology and endocrinology clinicians to drive prescriptions and relay clinical benefits; in 2024 Rayaldee net sales were reported at $58 million, reflecting focused uptake in chronic kidney disease-mineral bone disorder (CKD-MBD) segments. The company tailors marketing spend by segment, concentrating samples, medical education, and payer outreach to maximize ROI and prescription growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOPKO pursues acquisitions of undervalued healthcare assets—completing ~12 deals from 2019–2024—using rigorous financial models and due diligence to drive post-merger integration and synergies aimed at cutting costs 10–25% and accelerating revenue growth.\u003c\/p\u003e\n\u003cp\u003eManagement sees strategic investments as diversification: allocated ~$220m to minority stakes in 2024 to enter high-growth specialty diagnostics and rare-disease markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 deals (2019–2024)\u003c\/li\u003e\n\u003cli\u003e10–25% targeted cost synergies\u003c\/li\u003e\n\u003cli\u003e$220m minority investments in 2024\u003c\/li\u003e\n\u003cli\u003eFocus: diagnostics, rare diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and IP Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA and global approvals is a continuous task for OPKO Health (ticker OPK), which since 2023 spent roughly $45–60m annually on regulatory affairs to advance biologics and diagnostics through clinical and clearance pathways.\u003c\/p\u003e\n\u003cp\u003eThe company also actively enforces a ~120‑family patent portfolio to deter generics, preserving high gross margins (recent OPKO gross margin ~58% in 2024) tied to proprietary therapeutics and assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual regulatory spend ~45–60m (2023–2024)\u003c\/li\u003e\n\u003cli\u003ePatent portfolio ~120 families (2025)\u003c\/li\u003e\n\u003cli\u003eGross margin ~58% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpko: $254M R\u0026amp;D, $805M labs, 100M tests — scaling CTP platform, 58% gross margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko runs R\u0026amp;D (FY2024 R\u0026amp;D $254M) advancing CTP half-life platform (2–5x preclinical), operates BioReference labs (100M tests, lab revenue $805M FY2024), sells Rayaldee (net sales $58M 2024), pursues M\u0026amp;A (12 deals 2019–2024), minority stakes ($220M 2024), regulatory spend $45–60M, patent portfolio ~120 families, gross margin ~58%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$254M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio‑Ref tests (2024)\u003c\/td\u003e\n\u003ctd\u003e100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab revenue FY2024\u003c\/td\u003e\n\u003ctd\u003e$805M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayaldee sales 2024\u003c\/td\u003e\n\u003ctd\u003e$58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A deals 2019–2024\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinority investments 2024\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e$45–60M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families (2025)\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin 2024\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Opko Business Model Canvas you’ll receive after purchase—not a mockup or sample—and it contains the same structured content and layout shown here.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get this full document in editable formats, ready for presenting, editing, and implementing without any hidden pages or altered content.\u003c\/p\u003e\n\u003cp\u003eWe provide the live, complete deliverable so what you see is precisely what you’ll own and use for strategy and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749843546489,"sku":"opko-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/opko-business-model-canvas.png?v=1772219128","url":"https:\/\/growthsharematrix.com\/products\/opko-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}